GlobeNewswire: INNATE PHARMA Contains the last 10 of 608 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:14:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/09/23/2301847/0/en/Number-of-Shares-and-Voting-Rights-of-Innate-Pharma-as-of-September-1-2021.html?f=22&fvtc=4&fvtv=20104Number of Shares and Voting Rights of Innate Pharma as of September 1, 20212021-09-23T05:00:00Z<![CDATA[MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:]]>https://www.globenewswire.com/news-release/2021/09/23/2301849/0/en/Number-of-Shares-and-Voting-Rights-of-Innate-Pharma-as-of-September-1-2021.html?f=22&fvtc=4&fvtv=20104Number of Shares and Voting Rights of Innate Pharma as of September 1, 20212021-09-23T05:00:00Z<![CDATA[Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:]]>https://www.globenewswire.com/news-release/2021/09/23/2301849/0/fr/Nouveau-nombre-d-actions-et-de-droits-de-vote-d-Innate-Pharma-au-1er-septembre-2021.html?f=22&fvtc=4&fvtv=20104Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 20212021-09-23T05:00:00Z<![CDATA[Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :]]>https://www.globenewswire.com/news-release/2021/09/17/2299034/0/en/Monalizumab-Data-from-COAST-Trial-Presented-at-ESMO-Congress-2021.html?f=22&fvtc=4&fvtv=20104Monalizumab Data from COAST Trial Presented at ESMO Congress 20212021-09-17T11:45:00Z<![CDATA[MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.]]>https://www.globenewswire.com/news-release/2021/09/17/2299035/0/en/Monalizumab-Data-From-COAST-Trial-Presented-at-ESMO-Congress-2021.html?f=22&fvtc=4&fvtv=20104Monalizumab Data From COAST Trial Presented at ESMO Congress 20212021-09-17T11:45:00Z<![CDATA[Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.]]>https://www.globenewswire.com/news-release/2021/09/17/2299035/0/fr/Pr%C3%A9sentation-de-Donn%C3%A9es-Issues-de-l-Essai-COAST-Comprenant-Monalizumab-au-Congr%C3%A8s-de-l-ESMO-2021.html?f=22&fvtc=4&fvtv=20104Présentation de Données Issues de l'Essai COAST Comprenant Monalizumab au Congrès de l'ESMO 20212021-09-17T11:45:00Z<![CDATA[Marseille, France, 17 sept. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd'hui qu’AstraZeneca (LSE/STO/Nasdaq : AZN) a présenté des résultats de l’essai randomisé de Phase 2 COAST au congrès annuel de l’ESMO (European Society for Medical Oncology) ce 17 septembre 2021.]]>https://www.globenewswire.com/news-release/2021/09/15/2297147/0/fr/Rapport-Financier-Semestriel-30-juin-2021.html?f=22&fvtc=4&fvtv=20104Rapport Financier Semestriel 30 juin 20212021-09-15T05:00:00Z<![CDATA[Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- RAPPORT FINANCIER SEMESTRIEL30 JUIN 2021]]>https://www.globenewswire.com/news-release/2021/09/15/2297149/0/en/Innate-Pharma-Reports-First-Half-2021-Financial-Results-and-Business-Update.html?f=22&fvtc=4&fvtv=20104Innate Pharma Reports First Half 2021 Financial Results and Business Update2021-09-15T05:00:00Z<![CDATA[MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release.]]>https://www.globenewswire.com/news-release/2021/09/15/2297150/0/en/Innate-Pharma-reports-first-half-2021-financial-results-and-business-update.html?f=22&fvtc=4&fvtv=20104Innate Pharma reports first half 2021 financial results and business update2021-09-15T05:00:00Z<![CDATA[Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release.]]>https://www.globenewswire.com/news-release/2021/09/15/2297150/0/fr/Innate-Pharma-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-et-l-avanc%C3%A9e-de-son-portefeuille-au-premier-semestre-2021.html?f=22&fvtc=4&fvtv=20104Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 20212021-09-15T05:00:00Z<![CDATA[Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui ses résultats financiers consolidés pour le premier semestre 2021. Les comptes consolidés sont joints au présent communiqué.]]>